Deep Brain Stimulation for Parkinson's Disease Treatment

We’re proud to announce the launch of our Deep Brain Stimulation (DBS) service, led by Consultant Neurologist, Professor Francesca Morgante and Consultant Neurosurgeon, Professor Erlick Pereira. Together, they bring expertise in the assessment and management of complex movement disorders, expanding our advanced neurological care offering for patients with conditions such as Parkinson’s disease, tremor, dystonia and chronic pain. DBS is an advanced treatment option that uses precisely targeted electrical impulses to reduce symptoms when medication no longer provides sufficient control. For selected patients, DBS can help improve daily function and quality of life. This milestone reflects our multidisciplinary approach and our commitment to bringing innovative treatments for complex neurological conditions. Read more: https://lnkd.in/gZTiUA5h Learn more about our Deep Brain Stimulation service: https://lnkd.in/g9ihZY2C #ClevelandClinicLondon #DeepBrainStimulation #DBS #Neurology #MovementDisorders

Your mid-stage PD patient is stiff and slow—and depressed. Medication alone isn't cutting it. What's left? 𝐌𝟏-𝐢𝐓𝐁𝐒 𝐢𝐧 𝐌𝐢𝐝-𝐒𝐭𝐚𝐠𝐞 𝐏𝐃 (2026, Neurotherapeutics) tested exactly that. 𝐖𝐡𝐚𝐭 𝐭𝐡𝐞𝐲 𝐟𝐨𝐮𝐧𝐝: • 𝐌𝐨𝐭𝐨𝐫 𝐬𝐜𝐨𝐫𝐞𝐬 𝐝𝐫𝐨𝐩𝐩𝐞𝐝 𝟑𝟎.𝟕% 𝐰𝐢𝐭𝐡 𝐫𝐞𝐚𝐥 𝐢𝐓𝐁𝐒 𝐯𝐬 𝟏𝟒.𝟑% 𝐰𝐢𝐭𝐡 𝐬𝐡𝐚𝐦 (p=0.036) • Depression fell 47.6%; anxiety dropped 37.9% • Responders showed strengthened brain connectivity between cerebellum, thalamus, and motor cortex 𝐁𝐨𝐭𝐭𝐨𝐦 𝐥𝐢𝐧𝐞: Five days of bilateral motor cortex stimulation produced clinically meaningful motor and mood gains in mid-stage disease. Have you considered noninvasive brain stimulation for your PD patients when meds plateau? Read the full trial summary on 𝐍𝐞𝐮𝐫𝐨.𝐖𝐢𝐤𝐢: https://lnkd.in/eMv2d8fc #NeuroTrials #Neurology #ClinicalTrials #Parkinsons #MovementDisorders

🧠 Time matters when it comes to brain health. For many people living with neurological diseases such as multiple sclerosis, the journey to an accurate diagnosis can take years. Delayed diagnosis may mean missed opportunities for timely care and treatment. On World Brain Day, we join the World Federation of Neurology's call for better access to neurological care, earlier diagnosis, and timely intervention worldwide. Because protecting brain health starts with helping people reach the right expertise at the right time. At Immunic, this mission resonates strongly with our focus on advancing research in MS, where early recognition and treatment may play an important role for improving long-term outcomes. #IMUX #Neurology

The message is clear: in MS, NMOSD and MOGAD, time matters. Earlier diagnosis, timely treatment and sustained protection of brain health are essential to improving long-term outcomes. At Aila Biotech, we are working to develop new approaches that address compartmentalised inflammation within the CNS, with the aim of protecting brain function in progressive neurological disease. #BrainHealth #MultipleSclerosis #PPMS #Neuroimmunology

Today is #WorldBrainDay!🧠 The MS Brain Health initiative has provided a framework for improving brain health in MS, NMOSD and MOGAD. It’s landmark Brain Health: Time Matters report has been used by healthcare professionals, patient organisations and policymakers to improve diagnosis, treatment and care. We're excited that MSIF is now leading the next chapter of the MS Brain Health Initiative. This World Brain Day, visit the MS Brain Health initiative website to learn more: https://lnkd.in/eDavWAg #WorldBrainDay #Neurology

🧠 World Brain Day 2026 | Brain Health: Access for All Neurological disorders claim an estimated 11 million lives each year. Yet 81% of these deaths occur in low- and middle-income countries, where access to neurological care is often most limited. This year's World Brain Day theme highlights a critical challenge facing global healthcare: ensuring that everyone, everywhere has access to timely diagnosis, treatment and support for neurological conditions. Today we join the World Federation of Neurology in championing Brain Health: Access for All. Explore the latest neurology education and insights: https://lnkd.in/eV8c5RRX World Federation of Neurology #WorldBrainDay #BrainHealth #Neurology #AccessForAll #WorldBrainDay2026 #NeurologicalDisorders

🧠 World Brain Day 2026 | Brain Health: Access for All Neurological disorders claim an estimated 11 million lives each year. Yet 81% of these deaths occur in low- and middle-income countries, where access to neurological care is often most limited. This year's World Brain Day theme highlights a critical challenge facing global healthcare: ensuring that everyone, everywhere has access to timely diagnosis, treatment and support for neurological conditions. Today we join the World Federation of Neurology in championing Brain Health: Access for All. Explore the latest neurology education and insights: https://lnkd.in/eV8c5RRX World Federation of Neurology #WorldBrainDay #BrainHealth #Neurology #AccessForAll #WorldBrainDay2026 #NeurologicalDisorders

🧠 World Brain Day 2026 | Brain Health: Access for All Neurological disorders claim an estimated 11 million lives each year. Yet 81% of these deaths occur in low- and middle-income countries, where access to neurological care is often most limited. This year's World Brain Day theme highlights a critical challenge facing global healthcare: ensuring that everyone, everywhere has access to timely diagnosis, treatment and support for neurological conditions. Today we join the World Federation of Neurology in championing Brain Health: Access for All. Explore the latest neurology education and insights: https://lnkd.in/eV8c5RRX World Federation of Neurology #WorldBrainDay #BrainHealth #Neurology #AccessForAll #WorldBrainDay2026 #NeurologicalDisorders

Delighted to share our latest work from Mayo Clinic: "Comparative Seizure Outcomes of Vagus Nerve Stimulation, Deep Brain Stimulation, and Their Combination in Lennox–Gastaut Syndrome." We reviewed 40 LGS patients treated at Mayo (2005–2024), analyzing 51 treatment epochs across three arms: VNS alone, DBS alone, and DBS with ongoing VNS. Key findings at 24 months: 🔹 VNS and DBS produced comparable median seizure reduction (50% vs. 59%, p = 0.54) 🔹 DBS + VNS reached 81% median reduction — significantly greater than DBS alone (43%) or VNS alone (50%) 🔹 56% of the DBS+VNS group dropped below 10 seizures/month, vs. 0% and 8% in the other arms Grateful to my co-authors and mentors at Mayo Clinic — Drs. Brian Lundstrom, Gregory Worrell, and the whole team. 🔗 DOI: 10.1002/ana.78308 #Epilepsy #Neuromodulation #DBS #VNS #LennoxGastautSyndrome #PediatricNeurology #Neurology

Autoimmune encephalitis has moved past the diagnostic era — antibody testing is no longer the bottleneck. New data presented at AAN Autoimmune Neurology 2026 show cumulative relapse burden independently predicts poor long-term functional and cognitive outcomes in LGI1-AE (OR 2.94), while rituximab significantly reduces relapse risk (HR 0.19). Meanwhile, the COAST study documents wide practice variation in second-line NMDAR-AE therapy — rituximab (60.3%), cyclophosphamide (13.5%), tocilizumab (4.0%) — with no consensus on regimen or duration. A new patient-reported outcome measure, LANTERN, may finally capture what conventional scales miss: the executive dysfunction and psychiatric burden that persist even when clinician-rated outcomes look “good.” Full clinical breakdown of the AANAI 2026 encephalitis data: https://lnkd.in/ejqb3yQv #AutoimmuneNeurology #AANAI2026 #Neurology #Encephalitis #MedEd